Allogeneic Therapy

CD33 CRISPR/Cas9 gene-edited donor allograft in patients with AML at risk of relapse post-HSCT 5:15
CD33 CRISPR/Cas9 gene-edited donor allograft in patients with AML at risk of relapse post-HSCT
John DiPersio • 21 Feb 2023
Exploring the potential role of CD7-targeting CAR-T cells in T-ALL 2:21
Exploring the potential role of CD7-targeting CAR-T cells in T-ALL
Maksim Mamonkin • 10 Feb 2023
CARBON trial: investigating CTX110 allogeneic CRISPR-Cas9–engineered CAR-Ts in R/R LBCL 1:23
CARBON trial: investigating CTX110 allogeneic CRISPR-Cas9–engineered CAR-Ts in R/R LBCL
Constantine Tam • 12 Dec 2022
The safety and efficacy of UCART123v1.2 in R/R AML: results from AMELI-01 2:52
The safety and efficacy of UCART123v1.2 in R/R AML: results from AMELI-01
David Sallman • 11 Dec 2022
CYP-001 in adults with steroid-resistant GvHD 3:00
CYP-001 in adults with steroid-resistant GvHD
Ross Macdonald • 19 Apr 2022
SCUlpTOR: CYP-004 in osteoarthritis 2:56
SCUlpTOR: CYP-004 in osteoarthritis
Ross Macdonald • 19 Apr 2022
Addressing challenges in using MSCs in cell therapies 3:00
Addressing challenges in using MSCs in cell therapies
Ross Macdonald • 19 Apr 2022
Generating iSPC-derived MSCs with the Cymerus™ Platform 2:34
Generating iSPC-derived MSCs with the Cymerus™ Platform
Ross Macdonald • 19 Apr 2022
Optimizing the upscaling and outscaling of CAR T-cell therapies 4:06
Optimizing the upscaling and outscaling of CAR T-cell therapies
Saskia Rösch • 6 Apr 2022
Adoptive T-cell therapy for immunosuppressed patients with COVID-19 4:13
Adoptive T-cell therapy for immunosuppressed patients with COVID-19
Lena Peter • 1 Apr 2022
Applying CRISPR-Cas technology in advancing autologous T-cell therapies 1:50
Applying CRISPR-Cas technology in advancing autologous T-cell therapies
Mateusz Legut • 30 Mar 2022
Allogeneic therapy highlights at Advanced Therapies Week 2022 0:46
Allogeneic therapy highlights at Advanced Therapies Week 2022
Jeff Liter • 27 Jan 2022
Adapting cell therapies to solid tumors 2:57
Adapting cell therapies to solid tumors
Nina Bauer • 26 Jan 2022
Advances in allogeneic γδ T cells 2:04
Advances in allogeneic γδ T cells
Jeff Liter • 27 Jan 2022
The logistics of manufacturing allogeneic therapies on a large scale 1:02
The logistics of manufacturing allogeneic therapies on a large scale
Julia Tarasenko • 26 Jan 2022
The changing landscape of hospital-based cell and gene therapy manufacturing 2:40
The changing landscape of hospital-based cell and gene therapy manufacturing
Greg Roumeliotis • 26 Jan 2022
The content of VJRegenMed is intended for healthcare professionals